Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DELAY
- 31 Aug 2018 Biomarkers information updated
- 06 Jul 2012 Status changed from active, no longer recruiting to completed, based on results presented at ADA.
- 12 Jun 2012 Final results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.